Clinical trials

  • LUTETIUM (177LU) EDOTREOTIDE for Neuroendocrine tumor
  • Fluorouracil for Resectable pancreatic head cancer
  • Golcadomide for Secondary central nervous system lymphoma|Relapsed primary central nervous system large B-cell lymphoma|Refractory primary central nervous system large B-cell lymphoma
  • VOSORITIDE for Hypochondroplasia
  • BAY 2927088 for HER2 mutation | Advanced solid tumors
  • RILIPRUBART for Chronic inflammatory demyelinating polyneuropathy
  • azacitidine for Myelodysplastic syndromes | Chronic myelomonocytic leukemia
  • RALUDOTATUG DERUXTECAN for Gastrointestinal cancers | Pancreatic ductal adenocarcinoma | Cholangiocarcinoma | Gallbladder cancer | Colorectal adenocarcinoma | Gastric adenocarcinoma | Gastroesophageal junction adenocarcinoma | Esophageal adenocarcinoma
  • REVUMENIB for Acute myeloid leukemia (NPM1-mutated)
  • dipyridamole; acetylsalicylic acid (ASA) for Unruptured intracranial saccular aneurysm
  • sacubitril, valsartan for Arrhythmogenic right ventricular cardiomyopathy
  • (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE for Peritoneal carcinomatosis | Colorectal cancer | Gastric cancer | Ovarian cancer | Pancreatic ductal adenocarcinoma